Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Maurice Jove"'
Publikováno v:
Journal of Pain Research
David Leiman,1,2 Maurice Jové,3 Gail Rosen Spahn,4 Pamela Palmer4 1HD Research, Houston, TX, USA; 2University of Texas at Houston, Department of Surgery, Houston, TX, USA; 3Atlanta Bone and Joint Specialists, Atlanta, GA, USA; 4Medical Affairs, Acel
Autor:
Pamela P. Palmer, Karen P. DiDonato, David Leiman, Maurice Jove, Jacob L Hutchins, Harold S. Minkowitz
Publikováno v:
Pain Medicine. 19:2058-2068
OBJECTIVE: To evaluate sufentanil sublingual tablet 30 mcg (SST 30 mcg) for postoperative pain in an older patient population with comorbidities. DESIGN: Multicenter, open-label, single-arm study. SETTING: Nine hospitals across the United States. SUB
Autor:
Bruce Ben-David, Mark A. Evashenk, Harold S. Minkowitz, David W. Griffin, Maurice Jove, Pamela Pierce Palmer
Publikováno v:
Anesthesiology. 123:434-443
Background: Complications with IV patient-controlled analgesia include programming errors, invasive access, and impairment of mobility. This study evaluated an investigational sufentanil sublingual tablet system (SSTS) for the management of pain afte
Autor:
Maurice, Jove, David W, Griffin, Harold S, Minkowitz, Bruce, Ben-David, Mark A, Evashenk, Pamela P, Palmer
Publikováno v:
Anesthesiology. 123(2)
Complications with IV patient-controlled analgesia include programming errors, invasive access, and impairment of mobility. This study evaluated an investigational sufentanil sublingual tablet system (SSTS) for the management of pain after knee or hi
Autor:
Maurice Jove, Alise S. Reicin, Michael H. Bourne, Kerstin Malmstrom, Paul Kotey, Steven M. Rhondeau, G. Lynn Rasmussen, Michelle L. Aversano, Jennifer Ang
Publikováno v:
Anesthesia & Analgesia. 101:1104-1111
In this randomized, double-blind, placebo-controlled, multicenter study we assessed the analgesic effect of etoricoxib (a new cyclooxygenase-2 inhibitor) in patients having had knee or hip replacement surgery. A total of 228 patients with moderate or
Publikováno v:
American journal of therapeutics. 21(6)
Desirudin, administered 30 minutes before total hip arthroplasty is superior to enoxaparin in preventing proximal deep vein thrombosis (DVT) and pulmonary embolism (PE) with similar bleeding. The purpose of this study was to determine the safety of d
Autor:
Mark A. Evashenk, Pamela Pierce Palmer, Harold S. Minkowitz, Maurice Jove, Bruce Ben-David, David W. Griffin
Publikováno v:
Survey of Anesthesiology. 60:38
Background:Complications with IV patient-controlled analgesia include programming errors, invasive access, and impairment of mobility. This study evaluated an investigational sufentanil sublingual tablet system (SSTS) for the management of pain after
Publikováno v:
Blood. 124:5085-5085
INTRODUCTION. Desirudin is a recombinant direct thrombin inhibitor (DTI) approved in the US for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients undergoing elective hip replacement surgery, and app
Autor:
Theodore Spiro, Phillip C. Comp, Richard J. Friedman, G.A. Gardiner, Thomas L. Whitsett, Glenn C. Landon, Maurice Jove, Gerhard Johnson
Publikováno v:
The Journal of Arthroplasty. 13:228